

announces the following Federal advisory committee meeting.

**NAME:** National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE).

**TIMES AND DATES:** 9 a.m.–4:30 p.m., December 6, 2004; 9 a.m.–12 noon, December 7, 2004.

**PLACE:** Westin Buckhead Atlanta Hotel, 3391 Peachtree Road, NE., 30326, telephone (404) 365–0065, fax (404) 365–8787.

**STATUS:** Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

**PURPOSE:** The Secretary is authorized by the Public Health Service Act, Section 399G, (42 U.S.C. S 280f, as added by Public Law 105–392) to establish a National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect to: (1) Foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

**MATTERS TO BE DISCUSSED:** Agenda items include: An overview of effective strategies to reduce the risk of problem drinking and alcohol-exposed pregnancies; what is needed to implement effective programs in the service delivery system; alcohol advertising and adolescent girls; and a discussion of issues presented. Additional agenda items include: Prevention and Post-Exposure working group sessions; updates from Task Force members on current initiatives; an update on activities from the Interagency Coordinating Committee on Fetal Alcohol Syndrome, the CDC and other Federal agencies; future topics, and scheduling the next meeting.

Agenda items are subject to change as priorities dictate.

**FOR FURTHER INFORMATION CONTACT:** R. Louise Floyd, DSN, RN, Designated Federal Official, National Center on Birth Defects and Developmental Disabilities, CDC, 1600 Clifton Road, NE., (E–86), Atlanta, Georgia 30333, telephone (404) 498–3923, fax (404) 498–3550.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: October 27, 2004.

**B. Kathy Skipper,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04–24391 Filed 11–1–04; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### The Board of Scientific Counselors, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) and the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry (ATSDR) announce the following committee meeting:

**Name:** Board of Scientific Counselors (BSC), National Center for Environmental Health/Agency for Toxic Substances and Disease Registry (NCEH/ATSDR).

**Time and Dates:** 8:30 a.m.–5 p.m., November 18, 2004, 8:30 a.m.–12:30 p.m., November 19, 2004.

**Place:** CDC Headquarters facility, 1600 Clifton Road, Atlanta, GA 30333.

**Status:** Open to the public for observation, limited only by the space available. The meeting room accommodates approximately 100 people.

**Purpose:** The Secretary, and by delegation, the Director of the Centers for Disease Control and Prevention and the Administrator of the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry, are authorized under section 301 (42 U.S.C. 241) and section 311 (42 U.S.C. 243) of the Public Health Service Act, as amended, to (1) conduct, encourage, cooperate with, and assist other appropriate public authorities, scientific institutions, and scientists in the conduct of research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and other impairments; (2) assist States and their political subdivisions in the prevention of infectious diseases and other preventable conditions and in the promotion of health and well-being; and (3) train State and local personnel in health work. The Board of Scientific Counselors, NCEH/ATSDR provides advice and guidance to the Secretary, HHS; the Director, CDC and Administrator, ATSDR; and the Director, NCEH/ATSDR, regarding program goals, objectives, strategies, and priorities in fulfillment of the agencies' mission to protect and promote people's health. The Board provides advice and guidance that will assist NCEH/ATSDR in ensuring scientific quality, timeliness, utility, and dissemination of

results. The Board also provides guidance to help NCEH/ATSDR work more efficiently and effectively with its various constituents and to fulfill its mission in protecting America's health.

**Matters To Be Discussed:** The agenda items for the meeting on November 18–19, 2004, will include but are not limited to an update on future initiatives; update on NCEH/ATSDR consolidation and accomplishments; reports on the Program Peer Review and the Community and Tribal subcommittees and the Health Department Workgroup; update on NCEH/ATSDR strategic priorities; report on social/behavioral sciences at NCEH/ATSDR; a review of the ATSDR Draft Dioxin Soil Policy Guidelines; and a presentation on the Emergency Preparedness and Response activities at NCEH/ATSDR.

Agenda items are tentative and subject to change.

#### For Further Information Contact:

Individuals interested in attending the meeting, please contact Sandra Malcom, Committee Management Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E–28, Atlanta, GA 30303; telephone 404/498–0003, fax 404/498–0059; e-mail: [smalcom@cdc.gov](mailto:smalcom@cdc.gov). The deadline for notification of attendance is November 12, 2004.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.

Dated: October 27, 2004.

**B. Kathy Skipper,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04–24389 Filed 11–1–04; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2002E–0340]

#### Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON)

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined the regulatory review period for GANIRELIX ACETATE INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the